Detalhe da pesquisa
1.
Clinical features and prognostic factors in solitary plasmacytoma.
Br J Haematol
; 172(4): 554-60, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26684545
2.
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Lancet Oncol
; 15(3): 333-42, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24525202
3.
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.
Haematologica
; 99(10): 1611-7, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25015938
4.
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Br J Haematol
; 160(5): 649-59, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23293914
5.
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
Blood
; 117(11): 3025-31, 2011 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-21228328
6.
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Haematologica
; 98(5): 784-8, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23242595
7.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol
; 9(6): e403-e414, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550060
8.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med
; 359(9): 906-17, 2008 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-18753647
9.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Eur J Haematol
; 86(5): 372-84, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21366694
10.
Monoclonal antibodies in multiple myeloma.
Panminerva Med
; 63(1): 21-27, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32955188
11.
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.
Haematologica
; 100(8): e328-30, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25840600
12.
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Eur J Haematol
; 84(3): 223-8, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19930441
13.
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts.
Eur J Haematol
; 82(2): 93-105, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19018865
14.
Surgery for vertebral involvement in multiple myeloma.
J Neurosurg Sci
; 62(1): 10-15, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26472142
15.
MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
Front Immunol
; 9: 926, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29765374
16.
Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy.
Cardiovasc Hematol Agents Med Chem
; 14(1): 68-74, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27048320
17.
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 33(30): 3459-66, 2015 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26282661
18.
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
J Clin Oncol
; 33(26): 2863-9, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26240224
19.
Apoptosis susceptibility and cell-cycle distribution in cells from myelodysplastic syndrome patients: modulatory in-vitro effects of G-CSF and interferon-alpha.
Leuk Lymphoma
; 45(7): 1437-43, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15359645
20.
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
J Clin Oncol
; 28(13): 2259-66, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20368561